/PRNewswire/ Inbiomotion SL, a company developing a unique single-gene-based biomarker for the personalized adjuvant treatment of early-stage (stage I-III).
Race to Beat Women s Cancers miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Best Life: New drug treating triple negative breast cancer
Best Life: Treatment for tripe-negative breast cancer By Ivanhoe Broadcast News | March 16, 2021 at 7:57 AM CDT - Updated March 16 at 6:17 PM
PITTSBURGH, Pa. (Ivanhoe Newswire)â About 15 percent of all women diagnosed with breast cancer have triple-negative breast cancer, meaning drugs that target estrogen, progesterone, and HER-2 proteinâwonât work. In the past, if the cancer returned, patients have had very few options. More on a newly approved drug that is stopping the cancer in its tracks.
Jane Ellen Keenan is a cancer warrior, battling triple-negative breast cancer since 2013. She had six months of chemo, and surgery. The cancer was gone . for a time.
Estrogen receptor (ER) is present in 85% of all breast cancers, and more than 90% of ER+ positive breast cancers also contain the AR which has been demonstrated to be an important therapeutic target in ER+ breast cancer. Enobosarm is an oral drug that selectively targets the AR in breast cancer without having the unwanted virilizing androgen adverse side effects including facial hair, acne, increase in hematocrit, or liver toxicity, while having potential clinical benefits including increasing muscle and physical function as well addressing cancer treatment induced bone loss and fractures. Enobosarm has extensive nonclinical and clinical experience having been evaluated in 25 separate clinical studies with 2,091 enrolled patients, including three Phase 2 clinical studies in advanced breast cancer. There are also at least two enobosarm investigator-initiated Phase 2 clinical studies in advanced breast cancer.